Clinical features and genotype of adenine phosphoribosyltransferase deficiency in iceland
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
CitationAm. J. Kidney Dis. 2001, 38(3):473-80
AbstractThe purpose of this study was to characterize the clinical, diagnostic, and prognostic features of adenine phosphoribosyltransferase (APRT) deficiency in Icelandic patients, as well as determine their genotype. Medical records of all known patients in Iceland were reviewed. Urinalysis and polymerase chain reaction-based DNA mutation analysis were performed in all patients, siblings, and living parents of index cases. Twenty-three individuals homozygous for type I APRT deficiency were identified in 16 families from 1983 to 1998. There were 12 males and 11 females, and the median age at diagnosis was 37 years (range, 0.5 to 62 years). Seventeen patients were index cases and 6 patients were diagnosed during screening of first-degree relatives. Eighteen patients had symptomatic disease, 15 of whom experienced nephrolithiasis; 4 patients had mild to moderate renal insufficiency, 1 patient had advanced renal failure, and 1 patient died of uremic complications. Six patients experienced recurrent urinary tract infections and 3 infants had a history of reddish-brown diaper stains. Five patients were asymptomatic; 3 of these patients were diagnosed during routine urinalysis and 2 patients were identified during family screening. Urinary 2,8-dihydroxyadenine crystals were detected in all cases, except for the patient who died of end-stage renal failure. All 23 patients were homozygous for the same mutation (D65V) in the APRT gene. Allopurinol therapy successfully prevented further stone formation and significantly improved renal function in most patients with renal insufficiency. Our results suggest that APRT deficiency may be more common than previously recognized and can lead to severe renal failure if left untreated.
DescriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links field
- Family study of 2,8-dihydroxyadenine stone formation: report of two cases of a compound heterozygote for adenine phosphoribosyltransferase deficiency (APRT*J/APRT*Q0).
- Authors: Suzuki K, Kobayashi S, Kawamura K, Kuhara T, Tsugawa R
- Issue date: 1997 May
- Chronic renal failure in a mouse model of human adenine phosphoribosyltransferase deficiency.
- Authors: Stockelman MG, Lorenz JN, Smith FN, Boivin GP, Sahota A, Tischfield JA, Stambrook PJ
- Issue date: 1998 Jul
- Detection of mutations in adenine phosphoribosyltransferase (APRT) deficiency using the LightCycler system.
- Authors: Funato T, Nishiyama Y, Ioritani N, Matsuki R, Yoshida K, Kaku M, Sasaki T, Ideguchi H, Ono J
- Issue date: 2000
- [2,8-dihydroxyadenine urolithiasis due to partial deficiency of adenine phosphoribosyltransferase: a case report].
- Authors: Ohne T, Fujito A, Koga K, Imaide Y, Uchida M
- Issue date: 1998 Oct
- Clinical, biochemical and molecular diagnosis of a compound homozygote for the 254 bp deletion-8 bp insertion of the APRT gene suffering from severe renal failure.
- Authors: Di Pietro V, Perruzza I, Amorini AM, Balducci A, Ceccarelli L, Lazzarino G, Barsotti P, Giardina B, Tavazzi B
- Issue date: 2007 Jan